Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with *Viscum album* extracts: A case report

Paul G Werthmann, Robert Kempenich, Gerlinde Lang-Avérous, Gunver S Kienle

**ORCID number:** Paul G Werthmann (0000-0002-1808-7787); Robert Kempenich (0000-0002-4499-0267); Gerlinde Lang-Avérous (0000-0002-4151-5567); Gunver S Kienle (0000-0001-9498-5944).

**Author contributions:** Werthmann PG, Kempenich R, Lang-Avérous G and Kienle GS contributed to the case report design. Kempenich R was the physician in charge who provided the patient's information. Lang-Avérous G provided the histologic images and confirmed the diagnosis and contributed the details about the histologic diagnosis. Werthmann PG and Kempenich R collected and provided the data. Werthmann PG was the principle author of the paper, had full access to all data, and is the guarantor. Kienle GS supervised the report and the publication process. All authors read and confirmed the final version of this article.

**Supported by:** Stiftung Integrative Medizin Stuttgart, Germany.

**Informed consent statement:** Informed consent was received from the patient for the publication of the report and accompanying images. The patient read the submission version of the report and confirmed its content.

**Conflict-of-interest statement:** The authors have declared no conflicts of interest.

**CARE Checklist (2016) statement:** This case report was prepared following the CARE Guideline.

**Open-Access:** This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).

**Abstract**

**BACKGROUND**

Advanced pancreatic cancer (aPC) has a poor prognosis with limited survival benefit from current standard treatment. *Viscum album* extracts (VAE) are used by many cancer patients, showing immune-stimulating effects, improved quality of life, and a survival benefit in patients with aPC.

**CASE SUMMARY**

A 59-year-old architect developed epigastric pain. A cystic lesion of the pancreas of 45-mm diameter was detected. In a follow-up magnetic resonance imaging, about one year later, multiple lesions were seen in the corpus and the tail of the pancreas; CA-19-9 was elevated to 58.5 U/mL. A distal pancreatectomy with splenectomy was performed, and a tumor of 7 cm × 5 cm × 3.5 cm was excised. Histologic investigation showed an intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma with invasion of the lymph vessels, perineural invasion, and positive nodes (2/27); surgical margins showed tumor cells, and the tumor was classified as pT3 N1 M0 R1. The patient was treated with radiation of the tumor bed and capecitabine/oxaliplatin followed by gemcitabine and FOLFIRINOX. Seven months after surgery, a liver metastasis was detected and treated with FOLFIRINOX. Four months after detection of the metastasis, the patient opted for additional treatment with VAE. Another month later, the metastasis was treated with radiofrequency ablation (RFA). Eight months later, the hepatic lesion recurred and was again treated with RFA. The
open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Received: November 1, 2018
Peer-review started: November 1, 2018
First decision: December 20, 2018
Revised: February 13, 2019
Accepted: March 1, 2019
Article in press: March 2, 2019
Published online: March 28, 2019

P-Reviewer: Ramia JM, Sandhu DS, Sugimoto M, Yang F
S-Editor: Ma RY
L-Editor: A
E-Editor: Ma YJ

Pancreatic cancer (PC) is a common malignancy (incidence 12.6/100,000 in the United States[1]), with a dismal prognosis (5-year survival of 2%[2]), especially in cases of locally advanced disease (median survival of 8-12 mo[3]). Intraductal papillary mucinous neoplasm (IPMN)-associated invasive adenocarcinoma of the pancreas is a histologic subtype of PC that has to be kept distinct from mucinous cystic neoplasms of the pancreas[4]; IPMN-associated invasive adenocarcinoma shows a better prognosis due to earlier onset of clinical symptoms compared to pancreatic ductal adenocarcinoma (PDA). However, prognosis of IPMN-associated and standard PDA are equally poor when compared by stage[5]. In all PC patients in which R0-resection seems feasible, surgery is recommended. R0-resected patients show a strong survival benefit compared to R1-resected patients[6]. Type of chemotherapy regimen - as primary or adjuvant treatment - is chosen according to tumor stage and performance status[7]. Radiofrequency ablation (RFA) is increasingly used in advanced PC (aPC); the procedure is safe, but comparative randomized trials on effectiveness are lacking[8-10].

Viscum album (European mistletoe, Viscum album L.) is a hemiparasitic shrub, growing on different host trees (oak, apple, pine and others). Aqueous Viscum album extracts (VAE) show a variety of antineoplastic properties including cytotoxic effects, apoptosis induction, immune stimulation, down-regulation of cancer genes (e.g., transforming growth factor β and matrix-metalloproteinases), reduction of cell migration, and reduction of tumor angiogenesis[11-14]. Active compounds of VAE are especially mistletoe lectins and viscoxotoxins, but also oligo- and polysaccharides, flavonoids, and triterpene acids[15, 16]. Injectable forms of VAE preparations (typically for subcutaneous use, or - as off-label use - for intralesional or intravenous application) are commercially available, and are used as supportive cancer therapy [17]. VAE show a common range of local reactions such as erythema at the injection site and general reactions like fever and flu-like symptoms. Rarely, pseudo allergic reactions can occur. VAE are safe, even when used in higher dosages[18].

CASE PRESENTATION

We present the case of a patient with aPC with R1-resection with development of liver metastasis during the course of treatment who showed an overall survival of 63 mo and a relapse-free survival of 39 mo under increasing VAE therapy. The possible synergistic effect on tumor control of RFA treatment and immune-stimulatory effects of VAE should be further investigated.

Key words: Pancreatic cancer; Integrative medicine; Viscum album extract; Radiofrequency ablation; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: We herewith present a case report of a patient with advanced pancreatic cancer with a survival time of 63 mo despite 2 times of relapse and continuous treatment with Viscum album extracts. The patient preserved a good quality of live, regained his weight after weight loss during chemotherapy and is currently working full-time in his job.

CONCLUSION

We present the case of a patient with aPC with R1-resection with development of liver metastasis during the course of treatment who showed an overall survival of 63 mo and a relapse-free survival of 39 mo under increasing VAE therapy. The possible synergistic effect on tumor control of RFA treatment and immune-stimulatory effects of VAE should be further investigated.

Citation: Werthmann PG, Kempenich R, Lang-Avérous G, Kienle GS. Long-term survival of a patient with advanced pancreatic cancer under adjunct treatment with Viscum album extracts: A case report. World J Gastroenterol 2019; 25(12): 1524-1530

URL: https://www.wjgnet.com/1007-9327/full/v25/i12/1524.htm
DOI: https://dx.doi.org/10.3748/wjg.v25.i12.1524
**Chief complaints**
A 59-year-old architect developed epigastric pain. He had a body mass index (BMI) of 30 (body weight of 92 kg, height of 175 cm) and was a nonsmoker.

**History of present illness**
Nothing to declare.

**History of past illness**
The patient had a history of bronchial asthma and suffered from gastroesophageal reflux disease, which was treated with esomeprazole.

**Personal and family history**
His father had died from metastatic colon cancer.

**Laboratory examinations**
CA-19-9 was elevated to 58.5 U/mL.

**Imaging examinations**
A cystic lesion of the pancreas of 45-mm diameter was seen in ultrasound and confirmed by computed tomography (CT) scan. In a follow-up magnetic resonance imaging (MRI), about one year after initial symptoms, multiple lesions were seen in the corpus and the tail of the pancreas (Figure 1A and B). A splenopancreatectomy was performed, and a tumor of 7 cm × 5 cm × 3.5 cm of the pancreatic tail was excised. Histologic investigation showed a poorly demarcated IPMN-associated hypermuzinous invasive adenocarcinoma with invasion of the lymph vessels, perineural invasion, and positive nodes (2/27); the tumor was 1 mm in the ventral resection margin, and the dorsal margin showed tumor parts (Figure 2). The tumor was classified as pT3 N1 M0 R1.

**FINAL DIAGNOSIS**
A patient with aPC.

**TREATMENT**
The patient was treated with radiation of the tumor bed (59.4 Gy) and capecitabine and oxaliplatin followed by gemcitabine and 8 cycles of FOLFIRINOX (folinic acid 390 mg, fluorouracil 4700 mg, irinotecan 340 mg, oxaliplatin 150 mg).

**OUTCOME AND FOLLOW-UP**
About 7 mo after surgery, a liver metastasis 2 cm in diameter in segment VIII was detected, and therefore treatment with FOLFIRINOX was started. Four months after detection of the metastasis the patient opted for additional continuous treatment with VAE (Iscador Qu 10 mg, 3 injections per week). Another month later, the metastasis was still unchanged despite chemotherapy and therefore treated with RFA. Eight months later, the hepatic lesion recurred within the scar tissue of the first metastasis, showing a lesion about 2 cm in diameter (Figure 1C and D). It was again treated by RFA and by a dose increase of VAE (Figure 3). The lesion regressed again and the patient stayed recurrence-free for the next 39 mo (as of the writing of this case report; for details of the disease and treatment course, see Figure 3).

**DISCUSSION**
We present a case of a 59-year-old patient with an aPC who underwent resection but showed positive margins (R1), with two relapses (liver metastases) after radiochemotherapy and RFA of metastases. The patient continuously received an adjunct treatment with VAE in increasing doses beginning shortly after detection of the liver metastasis and continuing until present. He showed prolonged survival and good health 63 mo after initial diagnosis. The patient had an advanced primary tumor, perineural invasion, lymph vascular invasion, node involvement, and positive resection margins - all of which are independent negative prognostic factors. In this patient, surgical excision was possible - a circumstance associated with an improved
Figure 1  Magnetic resonance imaging images of the tumor lesions. A and B: primary tumor lesion 2 mo before the initial diagnosis: cystic lesion at the location between body and tail of the pancreas with a size of $43 \times 38 \times 30$ mm; dilatation of the pancreatic duct of $13$ mm (A: T2 axial, B: T2 coronal); C and D: Relapsed hepatic lesion in segment VIII in month 20 after initial diagnosis (C: T1 axial, D: T1 coronal).

prognosis. However, median survival of PC patients who have undergone surgical excision, regardless of stage or other prognostic factors, is 19 mo (interquartile range, 10–42 mo)\(^{[18]}\).

VAE was repeatedly investigated in PC and showed cytotoxic effects in cell lines and animal studies (PA-TU-8902, PAXF 736, PAXF 546)\(^{[19–21]}\). Tröger et al\(^{[22]}\) found a survival benefit for aPC patients solely treated with VAE in a randomized controlled trial on overall survival. Similar results were seen by Axtner et al\(^{[23]}\) in an integrative oncology registry. In a phase 1 study of VAE and Gemcitabine in patients with advanced solid tumors (including PC) it could be shown, that VAE did not affect the pharmacokinetics of Gemcitabine\(^{[24]}\). VAE in PC is currently further investigated in clinical trials (NCT02948309).

RFA acts through direct thermal cell damage but shows additional immune stimulatory properties as tumor antigens and a variety of cytokines are released from the treated tumor tissue; increased numbers of tumor-specific T cells have been detected in RFA-treated patients\(^{[10]}\). Combination therapy of RFA with different immune-stimulatory agents showed promising results\(^{[25,26]}\). The combination of VAE with radiation - which, like RFA, leads to cell damage and to a release of antigens - proved to be more effective than radiation alone in animal studies\(^{[27,28]}\). VAE shows several immune-stimulating properties like proliferation induction and increase of antigen presentation of dendritic cells, proliferation of CD4\(^+\) T cells, increase of natural killer cell-mediated cytotoxicity, and release of cytokines\(^{[14]}\).

**CONCLUSION**

We presume that VAE acted synergistically with RFA, leading to tumor control. Reports of combined treatment with RFA and VAE should be collected to determine whether further investigations in this area are worthwhile.
**Figure 2** Patient’s tumor, haematoxylin and eosin stain. A: × 100; B: × 200; C: × 400 invasive mucinous adenocarcinoma; D and E: (× 100) perineural invasion.

**Figure 3** Timeline of the patient with advanced pancreatic cancer. Gy: Radiotherapy in Gray; CAPOX: Capecitabine + oxaliplatin; GEMC: Gemcitabine; FOLIFIRINOX: Leucovorin + fluorouracil + irinotecan + oxaliplatin.

**ACKNOWLEDGEMENTS**

We are thankful to Dr. Helmut Kiene (IFAEMM) for revision of the manuscript.

**REFERENCES**
therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and

Gameiro SR

DOI: 10.1155/2013/964592

Evid Based Complement Alternat Med 2013; 11: 63-79

Monahan BP. NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with

Wallerstedt DB, Sannes TS, Stagl J, Johnson LL, Blackman MR, Grem JL, Swain SM, Mansky PJ

[PMID: 27485618 DOI: 10.1186/s12885-016-2594-5]

BMC Cancer 2016; 16: 49-58

BMC Cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Ann Oncol 2015; 26 Suppl 5: s6-v68

Hooi YQ, Wang P, Zhu XY, Shen YH, Wang K, Shi WD, Lin JJ, Meng QZ, Chen Z, Chen H.

Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy.

Eur J Cancer 2015; 52: 1431-1439

Huang Z, Zhang Y, Xie Y, Song Q, Li H, Tan C, Huang N, Xiong W, Wang M, Meng Z, Lin F, et al.

Radiofrequency ablation of pancreatic ductal adenocarcinoma: The past, the present and the future.

World J Gastrointest Oncol 2015; 7: 6-11

Huang X, Zeng H, Wang C, Meng Z, Zou L, Gu X, Luo Y, Wang Y, Chen L, Li J, et al.

Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: An analysis of safety and efficacy.

Eur J Cancer 2015; 52: 1431-1439

Kienle GS, Grugel R, Kiene H. Safety of higher dosages of Viscum album L. in animals and humans--a systematic review of prospective clinical trials on complementary cancer therapy.

Eur J Med Res 2011; 16: 103-119

Kienle GS, Grugel R, Kiene H. Complementary cancer therapy: a systematic review of prospective clinical trials on cancer prevention and treatment.

RSC Adv 2016 [DOI: 10.1039/C5RA27381A]

Kriege M, Schütze F, Buchel MV, Krumme C, Bohnert L, Pape G, Kienle GS.

Coalition of Oncology in Palliative Care of Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med 2013; 2013: 964592

DOI: 10.1155/2013/964592

Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, Guha C, Hodge JW. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and...
mediates local and distal tumor regression. PLoS One 2013; 8: e70417 [PMID: 23894654 DOI: 10.1371/journal.pone.0070417]

26 Li G, Staveley-O’Carroll KF, Kimchi ET. Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. J Clin Trials 2016; 6 [PMID: 25042519 DOI: 10.4172/2167-0870.1000257]

27 Jurin M, Zarković N, Hrzenjak M, Ilić Z. Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 1993; 50: 393-398 [PMID: 8233280 DOI: 10.1159/000227217]

28 von Bodungen U, Ruess K, Reif M, Biegel U. Kombinierte Anwendung von Strahlentherapie und adjuvanter Therapie mit einem Mistelextrakt (Viscum album L.) zur Behandlung des oralen malignen Melanoms beim Hund: Eine retrospektive Studie. Complement Med Res 2017; 24: 358-363 [PMID: 29241194 DOI: 10.1159/000485743]
